An observational trial to assess tocilizumab in patients with rheumatoid arthritis who received tocilizumab, or anti-tumour necrosis factor alpha therapy, as their first biologic therapy, versus those who received tocilizumab as either their first or subsequent biologic therapy

Trial Profile

An observational trial to assess tocilizumab in patients with rheumatoid arthritis who received tocilizumab, or anti-tumour necrosis factor alpha therapy, as their first biologic therapy, versus those who received tocilizumab as either their first or subsequent biologic therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Tocilizumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Infliximab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jul 2015 New trial record
    • 10 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top